87122-06-3Relevant academic research and scientific papers
Structure-activity studies of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes: A novel class of highly potent nicotinic receptor ligands
Breining, Scott R.,Melvin, Matt,Bhatti, Balwinder S.,Byrd, Gary D.,Kiser, Melanie N.,Hepler, Christopher D.,Hooker, Dawn N.,Zhang, Jenny,Reynolds, Leslie A.,Benson, Lisa R.,Fedorov, Nikolai B.,Sidach, Serguei S.,Mitchener, J. Pike,Lucero, Linda M.,Lukas, Ronald J.,Whiteaker, Paul,Yohannes, Daniel
, p. 9929 - 9945 (2013/01/16)
The potential for nicotinic ligands with affinity for the α4β2 or α7 subtypes to treat such diverse diseases as nicotine addiction, neuropathic pain, and neurodegenerative and cognitive disorders has been exhibited clinically for several compounds while p
SPIROLACTAM DERIVATIVES AND USES OF SAME
-
, (2011/05/05)
The present invention provides spirolactam derivatives of formula (I): wherein R1-R7 are as defined herein; or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and uses of the same.
PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS
-
Page/Page column 84, (2008/06/13)
Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas (1 or 2), as described herein. The compounds of Formulas (1 and 2) are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.
